Member Info for sadoldgit

The Hood does not care, as the Hood will fail to accept facts that either he cannot grasp or refuses to so as to support his own agenda.

Where have l led people?

Never once have l advised people to buy, as l am in no position to advise.

You have advised repetitively that people sell.

This is a fact.

I am here to see a compound on licenced or maybe a buyout before l sell heavily.

That is where the value lies.

I remember the Puma posting about Majwand.

His plan is to short the share then when it reaches its bottom, buy in and make whoosh loads of money on the rise.

You have the same plan.

I do believe that our real biggy in the bag is SDC1802. I am entirely in xgreement that we may have to give some of our ownership away on this one.

Potentially capable of 1 billion plus at late stage but a substantial amount of this may well be lost should we get involved in a partnership of some sort.

My belief is that Sareum had this as an option but deciding that this amount of loss could be removed by RF finance.

Ok if the SP remained high but as we can see not so good if it does not.

Regards

Price dependant on data results that will include biomarker data that will indicate areas that SDC1801 would be likely to show most potential.

Yes there are other inhibitors. Similar Tyk2 and Jak1 inhibitors,

They are not all the same. Breprocitinib has around similar selectivity for Tyk2 over Jak1

Molecular size being very important.

I have discussed this much in the past.

Our Molecules all 31 0f them are patented.

The compounds as they sat during candidate selection, preclinical evaluation at end of preclinical, phase 1a, phase lb and the price would rise considerably from.the previous stage.

Indications as to which areas of therapy gained on phase1a data along with biomarker data will indicate areas of greatest potential for market commercialisation.

Regards

On satisfactory safety data, SDC 1802 can enter phase 2 trials. Does the Hood accept this fact or disagree and if so on what basis would you make your argument?

Would the Hood care to place a value on the worth of this compound alone accepting the fact that we will have a compound SDC that can enter phase2 straight from end of preclinical?

Regards

Never been a Mr Orange on here!

The value at the time?

You have little to know knowledge of Sareum or the rorth or potential wort of either SDC1801 or SDC1802.

The value will rise considerably from end of preclinical to end of phase1.

Clearly you are out of your depth here.

Data results are what are required by the interested parties as stated in the 2022 AGM.

'WELL SHOW US SOME DATA'

Do you remember this or are you as l believe you are ignorant of this fact also?

Regards

BullorBears

You put:-

'Why take the CLN? They have no other options, it gets worse for SAR as a CLN doesn't even want to provide more finance to them!!'

They can raise funds via share dilution

They could take on a partnership

They could on licence 1801.

So why do you state no other options.

Sareum stated that this was what they saw as the best option.

The other option most likely would be to on licence at preclinical, however this would have meant a considerable drop in financial worth in Sareum

As for you stating no other option what do you base such an absurd ridiculous statement on?

Regards

Potnak, no idea on how many shares RF have left.

They may still of had a few left prior to this latest share issuance.

The agreement would need to be looked at in detail and not just Sareums released key points.

My own very rough guess is they have sold around 900k to 1,100k since the issuance.

Ideally we as the investor should be informed as to how much is owed and how much outstanding along with how many shares there are under RF control among with howmany shares we are obligated to issue to RF.

Regards.

Agree Potnak that balances don't need to be paid until August 25. That being in full.

However, if we see below there are clauses.

The amount currently owing is greater than 10% of market cap.

Amount currently outstanding is also greater than 1 million.

'The key terms of the Facility:

· RiverFort has committed to providing an Equity Prepayment Facility of up to £5 million.

· The First Deposit of £2 million.

· Two further committed deposits of £0.3 million each on the 3-month and 6-month anniversaries of the First Deposit (the "Further Deposits")

· A fourth deposit, on the 6-month anniversary of the date of the First Deposit, of up to £1.4 million (the "Fourth Deposit") subject to the Customary Conditions (defined below) and the following trading conditions:

a) the maximum amount deposited and outstanding being not greater than 10% of the market capitalisation of the Company at the time of the deposit.

b) the maximum amount drawn and outstanding being not greater than a 15x multiple to the 10-day and 20-day Average Daily Traded Value of the Company's ordinary shares.

c) maximum amount deposited and outstanding being not greater than £1 million prior to the deposit.

· Future deposits, to the balance of up to £1 million (the "Future Deposits"), may be mutually agreed between the Company and RiverFort.

· All deposits will be subject to customary conditions precedent (including sufficient authority to allot shares and grant warrants to the Investors and disapply pre-emption rights, and no material adverse change to the Company or its '

The other option to finance is the option to on licence on less financially beneficial terms.

That does not involve share dilution.

Correct me if l am wrong BullBears.

Regards

Surfie61, the science has not changed.

I continue to add.

I have easily added several times your initial investment in the past few weeks.

That is my perogative.

That is the fact and truth.

I have never ever once advised a poster to buy.

I have suggested to one or two on here if they don't like the investment then sell.

What is wrong with that?

I have at times expressed concerns with regards to funding.

But as l am informed by certain poster here nobody including the poster, reads my posts to the end. So they will not know anyway.

You have a poster on here along with his mates over on ADVN who paint a bad picture.

These posters have no credibility but are cunning.

They will try to divide and conquer.

You chose to believe them and recommend their posts that is your perogative.

Whilst having a positive approach l have never ever made a statement that sareum will be worth 14 pounds a share, a potential if all goes well, yes.

Many times l have also stated it may be a bumpy ride. That means up and down. We sit at a down at the moment. Sentiment is important as you must realise.

So whilst you are concerned about your current losses as to some extent all of us are why do you feed and support those that have an agenda to drive this SP as low as they can?

Expect the best but be prepared for the worst.

We normally end up with what we genuinely expect.

I am expecting the best, and you whether you know it or not are expecting the worse.

Try filling your mind with positives. I take this as an opportunity to add significantly at a low price.

You see this not as an opportunity but impending doom pushed into you by the constant repetitive

predictors of doom and gloom.

The ' listen to me person' who will try to undermine any poster with a slightly positive attitude.

I see successs where others see failure.

Yes l see risk and yes l see reward.

Regards and have a good day.

It is not good to have a weak mind.

So by that very statement either the individual is stating false information for whatever reason, or you like him are ignorant as to what l have posted

Surfie61 l have been adding for weeks on a nigh daily basis. Smallish 15k shares yesterday at 16.13 hrs was my last addittion.

Just over doubled my holding here.

The price is ridiculously low for what we have in the pipeline.

That is my belief and why l continue to buy. A similar belief to others.

Regards

Good morning Potnak.

I am pretty sure that Tim and Co have a good idea how phase 1a is going.

However, they cannot release any info regarding until all date is analysed.

Follow ups on trial volunteers will add some time.

Tim an Co can be confident of good results, that is about as close as you will get in an indication.

Pleased l have added considerably over past week or so.

Regards

You make sense there xviolet.

They could raise a placing if indeed it is needed to complete 1a.

Personally l think they have enough for end of 1a, but as Damion suggested would require the money for the trial so they can recuperate the 1.6 million tax credits at mid July.

Should they reach a stage whereby all data is recieved and proves satisfactory then a placing to a higher value maybe required unless a deal is struck with an on licensee

Regards

No, l was not talking to you Hood.

Looks like the only thing stupid is you.

What on earth possessed you to too invest in the first place?

Don't tell me you are invested and been invested for years.

TBC123 looks like we have at least a 3 way umbilical cord here. You the Hood and a couple of Bristols over on ADVN.

Post something of substance.

Regards

A mere 2% of Psoriasis market would suffice although in reality likely to be much higher.

https://finance.yahoo.com/news/psoriasis-treatment-market-size-surpass-131700867.html#:~:text=psoriasis%20treatment%20market%3F-,The%20global%20psoriasis%20treatment%20market%20size%20was%20valued%20at%20USD,8.8%25%20during%20the%20forecast%20period.

Regards

Early Jak inhibitors lacked selectivity. Yes they would have efficacy but at the same time off target effects caused by lack of selectivity.

No such thing as one size fits all.

Later generation inhibitors have greater selectivity and now we have an Allosteric inhibitor that is so selective its a ability to treat certain Indications is somewhat restricted due to lack of efficacy.

It does appear than in an effort caused by sheer greed by BMS to obtain this all singing and dancing inhibitor it will be out classed and bettered in many Indications.

BMS must have been extremely disappointed with the UC data results. Nowhere near achieving the endpoints.

Regarding Psoriasis, we are not the only pharma that believe they can better Deucravacitinib.

Of the firm belief we can better the Deucra PASI 75 score in around 12 weeks.

What a lovely report on Deucravacitinib.

https://www.dermatologytimes.com/view/deucravacitinib-a-year-in-review

From late 2014.

Interleukin-22 (IL-22) is an IL-10 family cytokine that was recently discovered to be released by T helper 17 (Th17) cells, Th22 cells, etc. Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of psoriasis. For instance, IL-22 can inhibit keratinocyte terminal differentiation and can induce psoriasis-like epidermis alterations; serum IL-22 levels were correlated with the disease severity of psoriasis patients, and IL-22 mRNA was positively expressed in the psoriatic skin lesions, but negatively expressed in the normal controls. All these findings suggest that IL-22 may be implicated in psoriasis; therapeutics targeting IL-22 may have promise as a potential therapeutic target for treating psoriasis. In the present review, we summarize recent advances on the role of IL-22 in the pathogenesis and treatment of psoriasis.'

From the this post and the previous post we can deduce that there is no reason as to why the SDC compound cannot out perform Deucravacitinib.

Allosteric Tyk2 cannot inhibit IL-22. Keratinocyte production therefore cannot be inhibited by allosteric Tyk2.

One thing for sure is, it is not of the benefit of BMS to have such a promising potential of a commercialised Tyk2 Jak1 inhibitor such as SAR-20347.

Regards